CLRB Valuation

Cellectar Biosciences Inc

Add to Watchlist

Advanced Chart

4.880

+0.39(8.686%)1D

Overview
Forecast
Valuation
Earnings

CLRB Relative Valuation

CLRB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLRB is overvalued; if below, it's undervalued.

Historical Valuation

Cellectar Biosciences Inc (CLRB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.58. The fair price of Cellectar Biosciences Inc (CLRB) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：4.65

Fair

-0.40

Trailing

Forward

0.00

EV/EBITDA

Cellectar Biosciences Inc. (CLRB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.22

EV/EBIT

Cellectar Biosciences Inc. (CLRB) has a current EV/EBIT of -0.22. The 5-year average EV/EBIT is -0.63. The thresholds are as follows: Strongly Undervalued below -2.33, Undervalued between -2.33 and -1.48, Fairly Valued between 0.22 and -1.48, Overvalued between 0.22 and 1.07, and Strongly Overvalued above 1.07. The current Forward EV/EBIT of -0.22 falls within the Historic Trend Line -Fairly Valued range.

0.00

Cellectar Biosciences Inc. (CLRB) has a current PS of 0.00. The 5-year average PS is 1.26. The thresholds are as follows: Strongly Undervalued below -8.83, Undervalued between -8.83 and -3.79, Fairly Valued between 6.30 and -3.79, Overvalued between 6.30 and 11.34, and Strongly Overvalued above 11.34. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Cellectar Biosciences Inc. (CLRB) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.05. The thresholds are as follows: Strongly Undervalued below -0.36, Undervalued between -0.36 and -0.20, Fairly Valued between 0.11 and -0.20, Overvalued between 0.11 and 0.26, and Strongly Overvalued above 0.26. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Cellectar Biosciences Inc. (CLRB) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.52. The thresholds are as follows: Strongly Undervalued below -4.21, Undervalued between -4.21 and -2.37, Fairly Valued between 1.32 and -2.37, Overvalued between 1.32 and 3.17, and Strongly Overvalued above 3.17. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Cellectar Biosciences Inc (CLRB) has a current Price-to-Book (P/B) ratio of 1.44. Compared to its 3-year average P/B ratio of 2.49 , the current P/B ratio is approximately -42.40% higher. Relative to its 5-year average P/B ratio of 2.20, the current P/B ratio is about -34.66% higher. Cellectar Biosciences Inc (CLRB) has a Forward Free Cash Flow (FCF) yield of approximately -241.16%. Compared to its 3-year average FCF yield of -158.10%, the current FCF yield is approximately 52.54% lower. Relative to its 5-year average FCF yield of -112.24% , the current FCF yield is about 114.86% lower.

1.46

P/B

Median3y

2.49

Median5y

2.20

-246.08

FCF Yield

Median3y

-158.10

Median5y

-112.24

Competitors Valuation Multiple

The average P/S ratio for CLRB's competitors is 0.70, providing a benchmark for relative valuation. Cellectar Biosciences Inc Corp (CLRB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CLRB.O

Cellectar Biosciences Inc

Pelthos Therapeutics Inc

Allarity Therapeutics Inc

Loss

13.81M

Performance Decomposition

Market capitalization of CLRB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CLRB in the past 1 year is driven by Unknown.